SAB Biotherapeutics (SABS) Accumulated Depreciation & Amortization (2020 - 2025)
SAB Biotherapeutics (SABS) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $17.5 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $17.5 million, compared with a TTM value of $17.5 million through Dec 2025, changed N/A, and an annual FY2025 reading of $17.5 million, changed N/A over the prior year.
- Accumulated Depreciation & Amortization was $17.5 million for Q4 2025 at SAB Biotherapeutics, up from $16.1 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $17.5 million in Q4 2025 and bottomed at -$24.0 million in Q1 2022.
- Average Accumulated Depreciation & Amortization over 5 years is $2.9 million, with a median of $7.6 million recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization fell 7.63% in 2021, then skyrocketed 150.3% in 2023.
- Year by year, Accumulated Depreciation & Amortization stood at -$16.0 million in 2021, then skyrocketed by 139.35% to $6.3 million in 2022, then skyrocketed by 57.87% to $9.9 million in 2023, then increased by 19.8% to $11.9 million in 2024, then soared by 47.51% to $17.5 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for SABS at $17.5 million in Q4 2025, $16.1 million in Q2 2025, and $11.9 million in Q1 2024.